Ayana Pharma

Company Overview

Snapshot

Founded in June 2012 by Prof. Yechezkel Barenholz and Avi Molcho, Ayana Pharma operates with 11–50 employees. The company has secured funding across one round from Integra Holdings and Yechezkel Barenholz. In October 2021, a generic cancer-killing drug developed by the company received FDA approval for marketing.

Business overview

Ayana Pharma specializes in developing liposome-based treatments for cancer, leveraging the benefits of the FDA-approved liposomal nanodrug Doxil. The company aims to expand the treatment uses and efficacy of its technology, making it more widely available for various conditions. Ayana Pharma operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals, drug discovery, and drug delivery, primarily serving healthcare providers and patients in the United States.

Strategic signal

In February 2022, Ayana Pharma participated in an experiment to investigate whether zero gravity could aid in cancer treatment by sending a drug to space. This initiative highlights the company's commitment to exploring innovative and unconventional avenues for drug development and efficacy enhancement, signaling a forward-looking approach to pharmaceutical research and a potential for breakthroughs in extreme environments.

Company Intelligence Q&A

What is Ayana Pharma's core focus?

Ayana Pharma develops liposome-based treatments for cancer, building on the technology of the FDA-approved liposomal nanodrug Doxil to expand its applications and availability.

When was Ayana Pharma founded and by whom?

Ayana Pharma was founded in June 2012 by Prof. Yechezkel Barenholz and Avi Molcho.

What significant regulatory milestone did Ayana Pharma achieve?

In October 2021, a generic cancer-killing drug developed by Ayana Pharma received approval for marketing from the FDA.

What unique research initiative did Ayana Pharma undertake in 2022?

In February 2022, Ayana Pharma sent a drug to space to investigate the potential role of zero gravity in cancer treatment, exploring novel approaches to drug efficacy.

Which investors have participated in Ayana Pharma's funding rounds?

Ayana Pharma has received funding from Integra Holdings and Yechezkel Barenholz.